Dr Fielding qualified in medicine from UCL and obtained her PhD from Cambridge University.
Following her first faculty position at Mayo Clinic Rochester MN USA, in the Department of Molecular Medicine, she returned to UCL Cancer Institute in 2003. She is a translational clinician-scientist working in the field of acute lymphoblastic leukaemia (ALL), with a emphasis on developing novel therapies and understanding the biological difference between adult and childhood ALL.
A personal research focus is development of attenuated measles virus as an oncolytic virotherapy for ALL. She chairs the UK’s National Cancer Research Institute Adult ALL Group and is Chief Investigator on the UK’s main academically-initated trials, UKALL14 and UKALL60+. Dr Fielding’s clinical practice focuses on ALL at the Royal Free London NHS Foundation Trust.